Ackerman D M, Leibman K C
Drug Metab Dispos. 1977 Jul-Aug;5(4):405-10.
The effect of experimental diabetes on hepatic drug metabolism was studied in male Holtzman rats. Treatment of animals with streptozotocin and 6-aminonicotinamide, both agents which produce an insulin-deficient animal, caused prolongation of hexobarbital sleeping times and inhibition of the rate of metabolism of both hexobarbital and, to a lesser extent, aniline in vitro. Treatment of animals with N-methylacetamide, a diabetogen which does not cause insulin deficiency in the animal but rather produces an insulin-resistant state, did not affect the metabolism in vitro of either hexobarbital or aniline. Neither insulin nor any of the diabetogenic agents had any direct effect on drug metabolism in vitro. Furthermore, hepatic microsomal protein and cytochrome P-450 contents were not significantly different in any of the diabetic animals from those of the control animals. Hyperglycemia produced by glucose infusion did not affect the metabolism of hexobarbital in vitro. The effects of streptozotocin and 6-aminonicotinamide appeared to be at least partially due to the presence of an inhibitor in the liver cytosol which correlated with elevated hepatic cyclic AMP concentrations.
在雄性霍尔茨曼大鼠中研究了实验性糖尿病对肝脏药物代谢的影响。用链脲佐菌素和6-氨基烟酰胺对动物进行处理,这两种药物都会使动物产生胰岛素缺乏,导致己巴比妥睡眠时间延长,并在体外抑制己巴比妥以及程度较轻的苯胺的代谢速率。用N-甲基乙酰胺对动物进行处理,N-甲基乙酰胺是一种致糖尿病药物,它不会使动物产生胰岛素缺乏,而是产生胰岛素抵抗状态,该处理对体外己巴比妥或苯胺的代谢均无影响。胰岛素和任何一种致糖尿病药物在体外对药物代谢均无直接影响。此外,任何一只糖尿病动物的肝脏微粒体蛋白和细胞色素P-450含量与对照动物相比均无显著差异。通过输注葡萄糖产生的高血糖症在体外不影响己巴比妥的代谢。链脲佐菌素和6-氨基烟酰胺的作用似乎至少部分归因于肝胞质溶胶中一种抑制剂的存在,该抑制剂与肝脏环磷酸腺苷浓度升高相关。